TROP2 antibody–drug conjugate: unique epitope engagement drives differentiated efficacy
Antibody Therapeutics · 29.06.2026 · 9 (3) · 248-258
DOI: 10.1093/abt/tbag018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 27.04.2026. Verfasst von Hang Chen und 29 weiteren Autor:innen. Beteiligte Einrichtung: RemeGen Biosciences, Inc., 650 Gateway Blvd, Suite 110, South San Francisco, CA 94080, United States. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: RemeGen Biosciences, Inc, RemeGen Co. Ltd.
Abstract (Originalsprache)
Background
Trophoblast cell surface antigen 2 (TROP2) is frequently overexpressed in various cancers and is associated with poor prognosis. While TROP2-targeted antibody–drug conjugates (ADCs), such as sacituzumab govitecan, sacituzumab tirumotecan, and datopotamab deruxtecan (DXD), achieved clinical success, the mechanisms underlying resistance to these therapies remain incompletely understood. Consequently, the full therapeutic potential of TROP2 ADCs has yet to be comprehended.
Methods
We developed R7059-DXD, a novel TROP2-targeted ADC featuring an antibody that binds an epitope that is distinct from those recognized by sacituzumab and datopotamab. The structural basis of epitope recognition was elucidated using cryo-electron microscopy (cryo-EM), complemented by binding affinity analyses across multiple surface-expressed TROP2 variants. Functional activity was systematically evaluated through in vitro antibody-dependent cellular cytotoxicity (ADCC) assays, in vitro ADC-mediated killing assays, and in vivo efficacy studies in tumor models, including resistant lines.
Results
The R7059 antibody exhibited high binding affinity across multiple TROP2 variants, addressing a key resistance mechanism. The cryo-EM structure analysis revealed that the R7059 epitope lies in the N-terminal domain of TROP2 and is distinct from the sacituzumab and datopotamab epitopes. Functionally, R7059 demonstrated potent antitumor activity through both ADCC-dependent and independent mechanisms, suggesting additional signaling effects. The R7059 ADC demonstrated robust efficacy in multiple preclinical tumor models, including those resistant to approved TROP2 ADCs.
Conclusions
R7059-DXD is a differentiated, epitope-distinct TROP2-targeted ADC with the potential to overcome resistance to existing therapies. These findings support its further clinical development as a novel treatment for TROP2-expressing malignancies, including in patients previously treated with sacituzumab- or datopotamab-based regimens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- RemeGen Biosciences, Inc., 650 Gateway Blvd, Suite 110, South San Francisco, CA 94080, United States.
- RemeGen Co., Ltd, Yantai, PR China.
ORCID-Profile: Hang Chen, Zhulun Wang
Förderung
- RemeGen Biosciences, Inc
- RemeGen Co. Ltd
Zitieren
APA
Chen, H., Min, X., Cheng, Q., Liu, L., Jiang, B., Wu, Y., Carbon, J. G., Nam, D., Zhou, J., Bobeica, S. C., Chen, S. P., Li, J., Sharkov, N., Dash, S., Ma, S., Hua, S., Wang, F., Rojas, A., Zhao, G., …, & Wang, Z. (2026). TROP2 antibody–drug conjugate: unique epitope engagement drives differentiated efficacy. Antibody Therapeutics, 9(3), 248-258. https://doi.org/10.1093/abt/tbag018
Vancouver
Chen H, Min X, Cheng Q, Liu L, Jiang B, Wu Y, et al. TROP2 antibody–drug conjugate: unique epitope engagement drives differentiated efficacy. Antibody Therapeutics. 2026;9(3):248-258. doi:10.1093/abt/tbag018
BibTeX
@article{Chen2026,
author = {Chen, Hang and Min, Xiaoshan and Cheng, Qingwen and Liu, Lin and Jiang, Brittany and Wu, Yinan and Carbon, Juliet G and Nam, Daeun and Zhou, Jing and Bobeica, Silvia C and Chen, Shih-Ping and Li, Jennifer and Sharkov, Nikolai and Dash, Subhadra and Ma, Shidong and Hua, Sujun and Wang, Fang and Rojas, Andres and Zhao, Guorui and Li, Shenjun and Wang, Hui and Zhang, Qinbin and Tao, Jing and Yu, Zhan Jiao and Wang, Lili and Zhang, Wei and Li, Yuanhao and Jiang, Jing and Fang, Jianmin and Wang, Zhulun},
title = {TROP2 antibody–drug conjugate: unique epitope engagement drives differentiated efficacy},
journal = {Antibody Therapeutics},
year = {2026},
volume = {9},
number = {3},
pages = {248--258},
doi = {10.1093/abt/tbag018}
}
EUVIMED